GMP Engineering & Owner Representative Services

We manage the design, construction and commissioning of high-tech pharmaceutical and biotech facilities. 20+ years of experience, 600+ global projects.


Core Services

Comprehensive GMP engineering and consulting solutions for pharmaceutical and biotech facilities

GMP

Facility Design

From concept to detailed design, ensuring compliance with PIC/S GMP and FDA regulations.

Cell Therapy

 Facilities

Specialized design and engineering for advanced therapy manufacturing.

Computer System

Validation

FDA 21 CFR Part 11 compliant validation for critical manufacturing systems.

Owner

Representative

Comprehensive project oversight and management to protect your interests throughout the facility lifecycle.

Services

Why Choose  Persimmon Engineering

Deep Industry Expertise

Two decades of hands-on experience in GMP facility engineering and owner representation.

Proven Track Record

Successfully delivered 600+ projects for leading pharmaceutical and biotech companies.

Local & Global Presence

Taiwan-based with international offices, combining local market knowledge with global best practices.

Flexible Resources

Scalable team structure to support projects of any size and complexity.

quotesArtboard 1 copy 2

Comprehensive owner representation for a $50M pharmaceutical manufacturing facility expansion including design review, construction supervision, and commissioning support.

Pfizer Hangzhou

Owner Representative

 Trends & Insights

GMP regulations and pharmaceutical engineering

By Austin Chuang April 10, 2026
Master the regulatory framework, essential qualifications, and organizational duties for a Good Distribution Practice (GDP) Responsible Person.
By Austin Chuang April 10, 2026
A comprehensive guide to maintaining pharmaceutical supply chain integrity, regulatory compliance, and robust quality management systems.
By Austin Chuang April 10, 2026
Navigate European and international GMP regulations for biotechnological products, focusing on process control, virus safety, and inherent variability.
By Austin Chuang April 10, 2026
Explore the mechanisms of stainless steel oxidation, rouging classifications, and actionable lifecycle management strategies to ensure GMP compliance in your pharmaceutical facility.
By Austin Chuang April 10, 2026
Prepare for the EMA's new 3-year work plan including updates to Annex 15, Annex 22, and key GMP chapters.
By Austin Chuang April 10, 2026
An in-depth analysis of Simtra BioPharma's CGMP violations, highlighting risks from equipment dead legs, failed CAPA, and systemic contamination.
By Austin Chuang April 10, 2026
Discover key GMP violations from the recent FDA Warning Letter to OraLabs Inc. Learn why rigorous Root Cause Analysis is critical for compliance.
By Austin Chuang April 10, 2026
An Indian lab faces FDA action for systemic data destruction, backdated records, and inspection obstruction. See how this impacts CGMP compliance.
By Austin Chuang April 10, 2026
Navigate the regulatory shift towards patient-centric quality attributes for autologous cell and gene therapies with expert insights.
By Austin Chuang April 10, 2026
How ignored Performance Qualification (PQ) failures and systemic dead legs in pharmaceutical water systems led to an FDA Warning Letter.